Fennec Pharmaceuticals Inc. (FENC)
- Previous Close
9.57 - Open
9.52 - Bid 9.26 x 100
- Ask 9.38 x 100
- Day's Range
9.18 - 9.65 - 52 Week Range
6.30 - 11.92 - Volume
143,207 - Avg. Volume
123,123 - Market Cap (intraday)
253.113M - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.60 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.33
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
www.fennecpharma.comRecent News: FENC
Performance Overview: FENC
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FENC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FENC
Valuation Measures
Market Cap
252.30M
Enterprise Value
269.99M
Trailing P/E
--
Forward P/E
30.40
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.67
Price/Book (mrq)
--
Enterprise Value/Revenue
12.70
Enterprise Value/EBITDA
-21.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-75.50%
Return on Assets (ttm)
-29.67%
Return on Equity (ttm)
--
Revenue (ttm)
21.25M
Net Income Avi to Common (ttm)
-16.05M
Diluted EPS (ttm)
-0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
13.27M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.35M
Research Analysis: FENC
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell